Our strong history of collaborative innovation began with three scientists coming together to use their organic, photochemical, and immunodiagnostic expertise to develop and commercialize diagnostic and medical products.
Surmodics was formed as Bio-Metric Systems, Inc. (BSI) in 1979. In 1987, the company shifted its strategic objective from contract research to the commercialization of its unique PhotoLink® surface modification and immobilization technologies, and in 1990, added the marketing of biomolecule stabilization products.
In July 1997, BSI changed its name to Surmodics, Inc. to provide a more accurate reflection of the company's current and future business focus in the field of surface modification. Surmodics became a public company (Nasdaq National Market: SRDX) on March 4, 1998.
In August 2007, Surmodics further broadened its product portfolio within the in vitro diagnostic market through the acquisition of BioFX Laboratories, a developer, manufacturer, and marketer of colorimetric and chemiluminescent substrates and several accessory reagents.
Today, Surmodics focuses its expertise in two ways: The Medical Device business unit is a leading provider of surface modification and drug delivery technologies in the areas of hydrophilic coatings and site-specific drug delivery. The In Vitro Diagnostics business unit specializes in the development and commercialization of products and technologies for the in vitro diagnostic market.
Surmodics has over 30 years of experience in the surface modification and in vitro diagnostics industries.